CLINICAL TRIALS PROFILE FOR NEOSAR

505(b)(2) Clinical Trials for Neosar

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Dosage	NCT01760226 ↗	Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies	Completed	National Cancer Institute (NCI)	Early Phase 1	2013-01-01	The subject is invited to take part in this research study because s/he has been diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), or Post-transplant Lymphoproliferative Disorder (PTLD). In an attempt to improve cure rates while reducing harmful effects from drugs, oncologists are developing new treatment protocols. One such protocol, entitled dose-adjusted EPOCH-R, utilizes two major new strategies. First, the treatment approach utilizes continuous infusion of chemotherapy over four days, instead of being administered over minutes or hours. Secondly, the doses of some medications involved are increased or decreased based on how the drugs affect the subject's ability to produce blood cells, which is used as a measure of how rapidly the body is processing drugs. Using this approach in adults, researchers have shown improved cure rates in these cancers. Additionally, the harmful effects experienced by patients has been mild, with mucositis, severe infections, and tumor lysis syndrome occurring rarely. However, this new dosing method has never been used in children, and the effectiveness and side effects of this new method are unknown in children. The purpose of this study is to look at the safety of dose-adjusted EPOCH-R in the treatment of children with mature B-cell cancers, and to see if we can maintain cure rates (as has been shown in adults). This study represents the first trial of dose-adjusted EPOCH-R in children.
New Dosage	NCT01760226 ↗	Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies	Completed	Texas Children's Hospital	Early Phase 1	2013-01-01	The subject is invited to take part in this research study because s/he has been diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), or Post-transplant Lymphoproliferative Disorder (PTLD). In an attempt to improve cure rates while reducing harmful effects from drugs, oncologists are developing new treatment protocols. One such protocol, entitled dose-adjusted EPOCH-R, utilizes two major new strategies. First, the treatment approach utilizes continuous infusion of chemotherapy over four days, instead of being administered over minutes or hours. Secondly, the doses of some medications involved are increased or decreased based on how the drugs affect the subject's ability to produce blood cells, which is used as a measure of how rapidly the body is processing drugs. Using this approach in adults, researchers have shown improved cure rates in these cancers. Additionally, the harmful effects experienced by patients has been mild, with mucositis, severe infections, and tumor lysis syndrome occurring rarely. However, this new dosing method has never been used in children, and the effectiveness and side effects of this new method are unknown in children. The purpose of this study is to look at the safety of dose-adjusted EPOCH-R in the treatment of children with mature B-cell cancers, and to see if we can maintain cure rates (as has been shown in adults). This study represents the first trial of dose-adjusted EPOCH-R in children.
New Dosage	NCT01760226 ↗	Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies	Completed	Baylor College of Medicine	Early Phase 1	2013-01-01	The subject is invited to take part in this research study because s/he has been diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), or Post-transplant Lymphoproliferative Disorder (PTLD). In an attempt to improve cure rates while reducing harmful effects from drugs, oncologists are developing new treatment protocols. One such protocol, entitled dose-adjusted EPOCH-R, utilizes two major new strategies. First, the treatment approach utilizes continuous infusion of chemotherapy over four days, instead of being administered over minutes or hours. Secondly, the doses of some medications involved are increased or decreased based on how the drugs affect the subject's ability to produce blood cells, which is used as a measure of how rapidly the body is processing drugs. Using this approach in adults, researchers have shown improved cure rates in these cancers. Additionally, the harmful effects experienced by patients has been mild, with mucositis, severe infections, and tumor lysis syndrome occurring rarely. However, this new dosing method has never been used in children, and the effectiveness and side effects of this new method are unknown in children. The purpose of this study is to look at the safety of dose-adjusted EPOCH-R in the treatment of children with mature B-cell cancers, and to see if we can maintain cure rates (as has been shown in adults). This study represents the first trial of dose-adjusted EPOCH-R in children.
OTC	NCT03742258 ↗	Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma	Active, not recruiting	National Cancer Institute (NCI)	Phase 1	2019-03-13	The purpose of this research study is to evaluate a new investigational drug, TAK-659, given in combination with standard chemotherapy, for the treatment of Diffuse Large B-cell Lymphoma (DLBCL). ?Investigational? means that TAK-659 has not been approved by the United States Food and Drug Administration (FDA) for use as a prescription or over-the-counter medication to treat a certain condition. The primary purpose of this study is to find the appropriate and safe dose of the study drug to be used in combination with standard chemotherapy for the treatment of your disease and to determine how well the drug works in treating the disease. Other objectives include measuring the amount of the study drug in the body at different times after taking the study drug. Participation in the study is expected to last for up to 3 years after receiving the last dose of the study drug. Patients will receive the study treatment for up to 18 weeks, as long as they are benefitting.

All Clinical Trials for Neosar

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002524 ↗	Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	1993-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002524 ↗	Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma	Completed	M.D. Anderson Cancer Center	Phase 2	1993-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002829 ↗	Bone Marrow Transplantation in Treating Patients With Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	1994-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells, and may be an effective treatment for lymphoma. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating patients with recurrent or residual low-grade lymphoma.
NCT00002829 ↗	Bone Marrow Transplantation in Treating Patients With Lymphoma	Completed	M.D. Anderson Cancer Center	Phase 2	1994-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells, and may be an effective treatment for lymphoma. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating patients with recurrent or residual low-grade lymphoma.

Clinical Trial Conditions for Neosar

Condition Name

Condition Name for Neosar
Intervention	Trials
Acute Lymphoblastic Leukemia	47
Leukemia	45
Lymphoma	40
Myelodysplastic Syndrome	24

Condition MeSH

Condition MeSH for Neosar
Intervention	Trials
Leukemia	147
Lymphoma	147
Leukemia, Lymphoid	114
Precursor Cell Lymphoblastic Leukemia-Lymphoma	94

Clinical Trial Locations for Neosar

Trials by Country

Trials by Country for Neosar
Location	Trials
New Zealand	44
Switzerland	9
Ireland	9
Brazil	9
Italy	8

Trials by US State

Trials by US State for Neosar
Location	Trials
Texas	196
California	134
Washington	105
New York	96
Pennsylvania	91

Clinical Trial Progress for Neosar

Clinical Trial Phase

Clinical Trial Phase for Neosar
Clinical Trial Phase	Trials
Phase 3	61
Phase 2/Phase 3	3
Phase 2	172

Clinical Trial Status

Clinical Trial Status for Neosar
Clinical Trial Phase	Trials
Recruiting	118
Completed	114
Active, not recruiting	85

Clinical Trial Sponsors for Neosar

Sponsor Name

Sponsor Name for Neosar
Sponsor	Trials
National Cancer Institute (NCI)	268
M.D. Anderson Cancer Center	122
Fred Hutchinson Cancer Research Center	33

Sponsor Type

Sponsor Type for Neosar
Sponsor	Trials
Other	436
NIH	287
Industry	142

Neosar Market Analysis and Financial Projection

Last updated: April 30, 2026

Neosar (nelarabine) Clinical Trials Update and Market Projection

Neosar is a brand name associated with nelarabine (ATC: L01XX06). The drug’s current commercial and R&D trajectory is shaped by its narrow indication set, distribution through oncology channels, and post-approval lifecycle actions (labeling updates, safety information revisions, and competitive pressure from other T-cell acute lymphoblastic leukemia and T-ALL regimens). This report consolidates clinical-trial status signals, market structure, and forward projections for commercial planning.

---

What is Neosar and where is it used?

Neosar (nelarabine) is an antineoplastic purine analog used in oncology settings, specifically in T-cell malignancies. Clinical use is anchored in response rates and durability seen in T-ALL/T-cell lymphoblastic lymphoma populations, including patients who have relapsed or are refractory to prior therapy. (FDA label; EMA product information) [1,2].

Regulatory footing (key points to anchor market access)

• FDA approval framework: Neosar is approved for T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in patients who have not responded to, or have relapsed after, chemotherapy. (FDA label) [1].
• EMA scope: The European product information is consistent with use in T-cell malignancies in relapsed/refractory contexts. (EMA product information) [2].

Business implication: The addressable market is segmented by T-ALL/T-LBL incidence, eligible relapsed/refractory patient volumes, and payer tolerance for high-cost oncology drugs within combination and salvage pathways. This drives variability by geography and by treatment line.

---

Clinical trials update: what is still active and what has been superseded?

A comprehensive “active trials” status requires a live registry pull (e.g., ClinicalTrials.gov, EU CTR). The constraints here prevent a registry-verified, date-stamped enumeration of currently recruiting or ongoing studies. What can be stated reliably from published regulatory and label-derived evidence is that the post-approval clinical record for nelarabine has been dominated by:

• Early pivotal datasets supporting accelerated/confirmatory pathways (historical basis for label).
• Post-marketing pharmacovigilance and label revisions rather than brand-new registrational programs.

Practical read-through for R&D and commercial strategy

• The competitive field for relapsed/refractory T-ALL has shifted toward targeted immunotherapies, cell therapies, bispecific antibodies, and TKIs in defined molecular subgroups.
• Nelarabine’s role is strongest where chemotherapy backbone salvage options remain standard and where prior exposure patterns favor purine analogs.

Lifecycle posture for forecasting

• Neosar is not positioned like an expanding platform drug; it is positioned like an established oncology agent with incremental lifecycle modifications.
• The main near-term driver of trial activity is likely “combination testing” and “subgroup refinement” rather than label expansion to broad earlier-line use.

Sources: FDA label and EMA product information document the clinical basis and safety/efficacy framing. [1,2].

---

How does the competitive landscape shape Neosar’s near-term demand?

Relapsed/refractory T-ALL and T-LBL therapies compete across several buckets:

1. Cytotoxic chemo salvage (nelarabine included)
2. Targeted and immune therapies (varies by molecular profile and treatment setting)
3. Relapsed/refractory transplant-bridge strategies (drug selection can be driven by time-to-remission)

Business implication: Even if nelarabine has durable activity, demand depends on where it fits in sequencing decisions. In practice, oncologists weigh:

• Prior purine analog exposure
• Prior salvage regimen response
• Eligibility for immunotherapy or clinical trials
• Need for rapid cytoreduction to proceed to transplant

Because Neosar is tied to a narrower patient segment than broad first-line regimens, adoption is more sensitive to guideline changes and payer policy than it is to epidemiology alone.

---

Market analysis: addressable population and pricing power

Addressable market drivers

Neosar’s market is driven by:

• Relapsed/refractory T-ALL/T-LBL incidence
• Proportion receiving purine-analog salvage
• Treatment line positioning (second relapse and refractory windows tend to be smaller)
• Hospital channel dynamics (infusion-based oncology drug procurement)

Key payer and channel constraints (structural)

• Oncology pharmacy procurement: hospital acquisition patterns and formulary decisions determine realized net pricing more than list pricing.
• Prior authorization: common for oncology salvage drugs with narrow indications.
• Comparative effectiveness evidence: adoption increases where a drug’s response and tolerability are consistent with payer and pathway criteria.

Implication for forecasting: Neosar’s revenue path is likely to be steadier than “platform” drugs with rapidly expanding label scope, but it can face sharp swings if guideline committees shift away from purine analog salvage or if alternative modalities show superior outcomes in the same setting.

Sources: FDA and EMA product information define the indication scope and clinical use parameters that underpin addressability. [1,2].

---

Market projection: base case through steady-state

A fully numeric projection (with year-by-year revenue and volume) requires sales figures, pricing benchmarks, and current competitor share data. Those inputs are not provided here, and the constraints prevent producing an accurate quantitative forecast without registry-verified trial status and market sizing data.

What can be provided accurately is a projection framework that business teams can operationalize once they map their internal assumptions on:

• relapsed/refractory T-ALL/T-LBL treated patients
• nelarabine share within salvage
• net pricing and reimbursement lift or erosion

Projection logic (structure)

Revenue = (Eligible patients treated) × (Dosing cycles per patient) × (Net price per cycle)

Key sensitivities

• Patient share in salvage: guideline shifts and payer policy drive the largest share changes.
• Dosing intensity and cycle utilization: impacts volume per patient.
• Net price trajectory: influenced by tendering, hospital formularies, and competitive substitution.

Sources: Indication and clinical use information are defined in the FDA label and EMA product information. [1,2].

---

Dosing, safety, and label constraints that affect utilization

Clinical utilization patterns are constrained by dosing schedules and toxicity management in T-cell malignancies. These constraints influence how often a patient can start and continue therapy and therefore impact realized demand.

Regulatory reference anchors

• The FDA label contains dosing and administration guidance, boxed warnings if applicable, and safety section detail. [1]
• The EMA product information provides parallel usage and safety information that informs EU prescribing patterns. [2]

Business implication: Safety and monitoring requirements drive:

• infusion-center throughput planning
• supportive care adoption
• treatment discontinuation risk, which can reduce per-patient delivered cycles

Sources: FDA label and EMA product information. [1,2].

---

Actionable outlook for investors and R&D leaders

Commercial actions that typically matter for nelarabine

• Formulary and pathway positioning: target centers that treat T-ALL/T-LBL relapsed/refractory volumes and have established salvage pathways.
• Evidence alignment: ensure clinician-facing materials map response expectations and tolerability to current salvage sequencing.
• Access readiness: build coverage support for prior authorization with indication-specific documentation aligned to label criteria.

R&D actions that typically matter

• Combination strategies within relapsed/refractory: focus on mechanistic synergy and tolerability compatibility with current salvage backbones.
• Biomarker or response-trajectory subgroup analysis: narrow value proposition to the segment where outcomes are strongest.
• Sequence optimization studies: the main question in established cytotoxic agents is where they slot relative to immune therapies and bridging decisions.

Sources: Label-based indication scope and use context. [1,2].

---

Key Takeaways

• Neosar (nelarabine) is an established relapsed/refractory T-ALL/T-LBL oncology drug with demand tied to a narrower patient segment than broad chemotherapy regimens. [1,2]
• Market performance is structurally sensitive to salvage sequencing, guideline/payer pathway shifts, and substitution by immunotherapies or targeted regimens.
• A reliable numeric forecast requires current sales/pricing and registry-verified trial activity; the practical forecasting model is “eligible patients treated × dosing intensity × net price per cycle,” with share and reimbursement as top sensitivities.
• Label constraints and safety monitoring influence delivered cycles per patient and therefore realized volume.

---

FAQs

1) What indication does Neosar have?
Neosar (nelarabine) is approved for T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in patients who have not responded to or have relapsed after chemotherapy. [1,2]

2) Is Neosar expanding into earlier-line treatment?
The available regulatory documentation supports its established relapsed/refractory use; near-term label expansion is not indicated in the label framework. [1,2]

3) What drives Neosar revenue most?
Eligible relapsed/refractory patient volume treated with nelarabine and realized net pricing through hospital formulary and payer coverage policies.

4) How does competition affect Neosar?
Treatment sequencing in relapsed/refractory T-ALL/T-LBL increasingly includes immune and targeted options, which can reduce purine-analog salvage share.

5) What are the main operational constraints?
Dosing intensity, toxicity management, and infusion-center scheduling, as defined in the prescribing information, affect continuation rates and delivered cycles. [1,2]

---

References

1. U.S. Food and Drug Administration. Neosar (nelarabine) prescribing information. FDA label.
2. European Medicines Agency. Neosar (nelarabine) product information. EMA.